Skip to main content
SpringerLink
Log in

Statin–macrolide interaction risk: a population-based study throughout a general practice database

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

The myopathy risk associated with statin use increases in case of concomitant prescription of certain drugs, such as cytochrome P450 (CYP) system inhibitors (i.e., macrolides). The aim of this study was to assess whether concurrent statin/macrolide prescriptions at high interaction risk are commonly written in a general practice setting.

Methods

For this study, 156 general practitioners (GPs) with a patient population of almost 200,000 individuals, and participating in the Arianna database set up by “Caserta-1” Local health-Service Agency (ASL), were recruited. Within such a study sample, subjects receiving at least one statin/macrolide concomitant prescription during the year 2003 were identified. Sensitivity analysis was performed to assess the time distribution of high-risk macrolide prescriptions written within ±10 days from the statin prescription date.

Results

Among 190,124 patients included in the study, 7,176 (3.8%) received at least one statin prescription during the observation period. Of these, 228 (3.2%) were occasionally co-prescribed with any macrolide on the same date, in 153 cases (2.1% of statin users) the macrolide being of high interaction risk. In particular, 2.1% (55) of simvastatin users and 2.2% (64) of patients on atorvastatin were prescribed with high-risk macrolide on the same date versus 0.6% and 1.8% of patients prescribed with fluvastatin and pravastatin, respectively. Concerning GPs, 99 (63.5%) co-administered statin and macrolide at high interaction risk at least once.

Conclusions

Most GPs occasionally prescribed statin/macrolide at high interaction risk on the same date, despite the availability of therapeutic alternatives. Prevention strategies targeted to increase awareness of health professionals about the interaction risks of widely prescribed drugs are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Castelli WP et al (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835–2838

    PubMed  Google Scholar 

  2. Hebert PR et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomised trials. JAMA 278:313–321

    PubMed  Google Scholar 

  3. Gotto AM, Grundy SM (1999) Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on reducing the risk for coronary heart disease, 9th council meeting. Circulation 99:E1–E7

    Google Scholar 

  4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2003) ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158

    PubMed  Google Scholar 

  5. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109:III50–III57

    PubMed  Google Scholar 

  6. Farmer JA, Torre-Amione G (2000) Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 108:351–352

    Google Scholar 

  7. Mahley RW, Bersot TP (2001) Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman JG, Limbird LE (eds) Goodman& Gilman’s, the pharmacological basis of therapeutics, 10th edn. McGraw Hill, Medical Publishing Division, New York, pp 971–1002

    Google Scholar 

  8. Paoletti R, Corsini A, Bellosta S (2002) Pharmacological interactions of statins. Atheroscler 3:35–40

    Article  Google Scholar 

  9. Corsini A et al (1999) New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 84:413–428

    PubMed  Google Scholar 

  10. Australian Adverse Drug Reactions Bulletin 23 (1), February 2004

  11. Delaforge M et al (1988) Effects of roxithromycin on rat hepatic P 450 cytochromes: comparison with troleandomycin and erythromycin. Br J Clin Pract 42:67–69

    Google Scholar 

  12. Amacher DE et al (1991) Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicr Agents Chemother 35:1186–1190

    Google Scholar 

  13. Nahata M (1996) Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 37:133–142

    Google Scholar 

  14. Tinel M et al (1989) Effects of clarithromycin on cytochrome P450: comparison with other macrolides. J Pharm Exp Ther 250:746–751

    Google Scholar 

  15. Westphal JF (2000) Macrolides-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50:285–295

    PubMed  Google Scholar 

  16. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research: the use of general practice databases. J Pub Health Med 21:299–304

    Article  Google Scholar 

  17. Yang CC, Jick SS, Testa MA (2003) Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of co-morbidities and patient characteristics. Br J Clin Pharmacol 56:84–91

    PubMed  Google Scholar 

  18. Heerey A, Barry M, Ryan M, Kelly A (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169:176–179

    PubMed  Google Scholar 

  19. Hansten PD (2003) Drug interaction management. Pharm World Sci 25(3):94–97

    PubMed  Google Scholar 

  20. Herrlinger C, Klotz U (2001) Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroent 15:897–918

    PubMed  Google Scholar 

  21. Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Onc Hematol 48:133–143

    Google Scholar 

  22. Merlo J, Liedholm H et al (2001) Prescriptions with potential drugs interactions dispensed at Swedish pharmacies in January 1999: cross-sectional study. BMJ 323:427–428

    PubMed  Google Scholar 

  23. “NOTA 13” of Italian Medicines Agency (AIFA) Available at website: http://www.ministerosalute.it/imgs/C_17_bif_bollettino_25_file_itemName_4_filePdf.pdf. Accessed 16/05/2005

  24. Cenedella RJ (2003) Beware of combining erythromycin with a statin. J Am Osteopath Assoc 103:117

    Google Scholar 

  25. Hueston WJ, Mainous AG 3rd, Ornstein S, Pan Q, Jenkins R (1999) Antibiotics for upper respiratory tract infections. Follow-up utilization and antibiotic use. Arch Fam Med 8:426–430

    PubMed  Google Scholar 

  26. Maestre-Vera JR (2004) Treatment options in odontogenic infection. Med Oral Patol Oral Cir Bucal 9(Suppl 25–31):19–24

    Google Scholar 

  27. Saito M, Hirata-Koizumi M et al (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30:21–37

    PubMed  Google Scholar 

  28. Committee on Safety of Medicines (2004) Curr Probl Pharmacovigilance 30:1–2

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine and Pharmacology, Pharmacology Unit, University of Messina, Via Consolare Valeria-Gazzi, 98125, Messina, Italy

    Nadia Piacentini, Gianluca Trifiró & Vincenzo Arcoraci

  2. Caserta 1 Local Health Service, Caserta, Italy

    Michele Tari & Salvatore Moretti

Authors
  1. Nadia Piacentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianluca Trifiró
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Tari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvatore Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincenzo Arcoraci
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

UVEC group

Corresponding author

Correspondence to Gianluca Trifiró.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piacentini, N., Trifiró, G., Tari, M. et al. Statin–macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61, 615–620 (2005). https://doi.org/10.1007/s00228-005-0972-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0972-z

Keywords

Search

Navigation